Mar 21, 2023 / 12:30PM GMT
Operator
Good day and welcome to the Mereo Biopharma regulatory update conference call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Lee Roth, Senior Vice President of Investor Relations at Burns McClellan. Please go ahead.
Lee Roth - Burns McClellan Inc. - SVP, IR
Thanks, Jason. And once again, thanks to everybody for joining us today for the regulatory update on the alvelestat that program in alpha-1-antitrypsin deficiency disorder. Joining me on the call is Dr. Denise Scots-Knight, Chief Executive Officer at Mereo. Following prepared remarks by Dr. Scots-Knight, Dr. Jackie Parkin, SVP and Therapeutic Head, leading the clinical development of alvelestat for AATD-lung disease, and Dr. Suba Krishnan, Senior Vice President of Clinical Development, will join from a line for a Q&A session with the sell side.
Please note today's conference call will contain forward-looking statements, including statements regarding the company's expectations with respect to its proposed Phase 3 study evaluating
Mereo Biopharma Group PLC Corporate Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
